CLARITY is a study which aims to improve patient care pathways and to ensure that patients with suspected appendicitis receive the appropriate care that they need

| Submission date 20/08/2024 | Recruitment status Recruiting | Prospectively registered Protocol |
|-------------------------------|---|--|
| Registration date | Overall study status | Statistical analysis plan |
| 03/09/2024 | Ongoing | |
| Last Edited | Condition category | [X] Pecord updated in last year |
| 00/10/2024 | Digestive System | |

Plain English summary of protocol

Background and study aims

Appendicitis is a common condition where the appendix, a small part of the bowel, becomes inflamed. If untreated, it usually doesn't get better on its own, so the appendix is often removed through surgery. However, diagnosing appendicitis can be tricky because its symptoms can resemble other conditions. While doctors use blood tests and scans to help with the diagnosis, the way these are used varies across the UK, leading to some patients being misdiagnosed or undergoing unnecessary surgery. In fact, about 20% of people in the UK who have their appendix removed are found not to have had appendicitis after all, which is much higher than in other European countries.

The CLARITY study aims to improve how doctors diagnose and treat suspected appendicitis. The goal is to reduce unnecessary hospital admissions and surgeries by educating doctors on using the best evidence-based strategies to diagnose appendicitis more accurately.

Who can participate?

This study is focused on doctors, so it does not require patients to participate directly. However, patients with suspected appendicitis will benefit from the improved care pathways being tested.

What does the study involve?

For patients with suspected appendicitis, there won't be any changes to their care, and they won' t need to attend extra appointments or fill out surveys. The study is testing an educational intervention for doctors, which means the focus is on improving how doctors make decisions about diagnosing and treating appendicitis.

What are the possible benefits and risks of participating?

There are no risks for patients involved in this study since their usual care won't change. The potential benefit is that the study could lead to better diagnosis and treatment for appendicitis, reducing unnecessary surgeries and hospital stays.

Where is the study run from? University of Birmingham (UK)

When is the study starting and how long is it expected to run for? May 2024 to December 2025.

Who is funding the study? Investigator initiated and funded

Who is the main contact? Professor Dion Morton, dion.morton@uhb.nhs.uk

Study website https://claritytrial.co.uk

Contact information

Type(s) Public, Scientific, Principal Investigator

Contact name Prof Dion Morton

ORCID ID http://orcid.org/0000-0001-6784-1689

Contact details

Room 31, Fourth Floor Academic Department of Surgery University of Birmingham Heritage Building Birmingham United Kingdom B15 2TT +44 (0)1213718910 dion.morton@uhb.nhs.uk

Type(s)

Scientific

Contact name Dr James Keatley

ORCID ID http://orcid.org/0000-0001-7458-5644

Contact details ITM, Heritage Building Mindelsohn Way Birmingham United Kingdom B15 2TH +44 (0)7305907886 j.keatley@bham.ac.uk

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 334172

ClinicalTrials.gov number Nil known

Secondary identifying numbers RG_24-022, IRAS 334172

Study information

Scientific Title

SurgiCaL educAtion to Reduce IncorrecT care pathwaYs and enhance patient outcomes in right iliac fossa pain

Acronym

CLARITY

Study objectives

CLARITY is a study which aims to improve patient care pathways and to ensure that patients with suspected appendicitis receive the appropriate care that they need. We will do this by trying to reduce unnecessary admissions for appendicitis in the United Kingdom. CLARITY will test whether educating doctors who diagnose and treat appendicitis prompts them to use the best evidence strategies to diagnose appendicitis correctly. In turn this may enable doctors to reach the correct diagnosis earlier and to use admissions or surgery in patients that require them.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 29/05/2024, HRA and Health Care Research Wales (Health Research Authority, 2 Redman Place, London, E20 1JQ, United Kingdom; +44 207 104 8000; contact@hra.nhs.uk), ref: 24/HRA/2214

Study design

Multicentre parallel cluster randomized controlled trial with an effectiveness-implementation design

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s) Hospital

Study type(s) Diagnostic, Efficacy

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Improve patient care pathways in patients with suspected appendicitis

Interventions

The intervention is the CLARITY accurate diagnosis package, which is made up of three components: the evidence based education programme (EBP), an implementation checklist and local implementation strategies. The EBP is considered the main component of our intervention and will be delivered using a digital education platform to intervention sites.

There are two study arms: intervention and control. Randomisation of sites is carried out on Redcap using a 1:1 minimisation algorithm.

Intervention arm

Sites randomised to the intervention arm receive access to our intervention, the CLARITY evidence-based education programme. Doctors and clinicians within the acute surgical team, are encouraged to carry out the programme in a 4-week training period. This is followed by 8 weeks of data collection, during which routine data will be gathered for all consecutive patients aged 16-39 years who are referred to general surgery with right iliac fossa pain. The follow up is for 30 days, starting from the date of index admission or attendance to hospital. There is no patient level intervention.

Control Arm

Sites randomised to the control arm do not receive the intervention and continue with their routine practice. They are asked to complete an 8-week data collection period and 30 days follow up.

Intervention Type

Behavioural

Primary outcome measure

Non-operative admission rate (NOAR) defined as the proportion of patients admitted overnight with right iliac fossa pain who did not undergo an operation. Measured by review of patient notes at 30 days follow up. Measured by the patient's admission and discharge on different dates without any record of operative intervention during their stay. This excludes patients that are subsequently admitted to hospital with missed appendicitis and readmissions.

Secondary outcome measures

1. Negative appendicectomy rate (NAR). Defined as the proportion of patients that received a negative appendicectomy measured by review of patient notes at 30 days follow up.

2. Missed or delayed appendicitis. Proportion of patients that were not correctly diagnosed with appendicitis on their first hospital attendance and review by the surgical team. The diagnosis of appendicitis must be confirmed on radiological imaging or histology. Review of patient notes at 30 days follow up.

3. Readmission or re-attendance to hospital. Discharge from the care of the general surgical team and subsequent reattendance to hospital for RIF pain. Including all patients reattending with RIF pain or post-operatively. Excludes patients with missed appendicitis. Review of patient notes at 30 days follow up.

4. Reoperation (abdominal) for any cause, measured at 30 days follow up.

5. Surgical complications, as defined by the Clavien-Dindo classification system, measured at 30 days follow up.

6. Surgical site infection, as defined by the Centers for Disease Control criteria, measured at 30 days follow up.

7. Time from symptom onset to decision to operate and to skin incision (in hours) measured during index admission.

8. Radiological, percutaneous or laparoscopic drainage measured during index admission, measured at 30 days follow up.

9. The proportion of patients with complicated appendicitis (phlegmon, abscess or perforation), measured at 30 days follow up.

10. Admission to critical care (Level 2/3 care) for any length of time, measured during index admission.

11. Mortality (both inpatient and in the community from any cause), measured at 30 days follow up using patient notes.

Overall study start date

29/05/2024

Completion date

30/12/2025

Eligibility

Key inclusion criteria

Patients: 1. Age 16 - 39 years 2. Attending hospital with right iliac fossa pain

Health professionals: 1. Members of the acute general surgery team

Participant type(s) Patient, Health professional

Age group Adult

Lower age limit 16 Years

Upper age limit 39 Years

Sex Both

Target number of participants 4800

Key exclusion criteria

Patients:

- 1. Previous appendicectomy
- 2. Current pregnancy

3. Patients with RIF pain under the care of secondary teams (other than general surgery team)

Heath professionals:

 Doctors and allied health professionals that are not part of the acute general surgical team
 Members of the general surgical team that are not involved in the diagnostic assessment and management of patients with RIF pain

Date of first enrolment 23/08/2024

Date of final enrolment 01/12/2025

Locations

Countries of recruitment England

Scotland

United Kingdom

Wales

Study participating centre Bedfordshire Hospitals NHS Foundation Trust Lewsey Road Luton United Kingdom LU4 0DZ

Study participating centre

Barts Health NHS Trust

The Royal London Hospital 80 Newark Street London United Kingdom E1 2ES

Study participating centre Pilgrim Hospital Sibsey Road

Boston United Kingdom PE21 9QS

Study participating centre

Furness Hospitals NHS Trust Furness General Hospital Dalton Lane Barrow-in-furness United Kingdom LA14 4LF

Study participating centre Bronglais General Hospital Bronglais Hospital Caradoc Road

Aberystwyth United Kingdom SY23 1ER

Study participating centre Gloucestershire Royal Hospital Great Western Road Gloucester United Kingdom GL1 3NN

Study participating centre Western General Hospital Crewe Road South Edinburgh Lothian United Kingdom EH4 2XU

Study participating centre Heartlands Hospital Bordesley Green East Bordesley Green Birmingham United Kingdom B9 5ST

Study participating centre University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital Mindelsohn Way Edgbaston Birmingham United Kingdom B15 2GW

Sponsor information

Organisation University of Birmingham

Sponsor details

Research Governance Team Birmingham England United Kingdom B15 2TH +44 (0)7814 650 003 researchgovernance@contacts.bham.ac.uk

Sponsor type University/education

Website http://www.birmingham.ac.uk/index.aspx

ROR https://ror.org/03angcq70

Funder(s)

Funder type Other

Funder Name

Investigator Initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in peer-reviewed journal(s) and presentation at national and international conference(s).

Intention to publish date

30/12/2026

Individual participant data (IPD) sharing plan

The datasets generated during the study will be stored in a non-publicly available repository (Redcap - https://bistc.redcap.bham.ac.uk/).

Our participants are doctors and clinicians with the acute surgical team. The final dataset will comprise the datasets from all eligible patients. The data stored will include details on:

- Baseline characteristics
- Investigations performed
- Clinical management
- Clinical outcomes at 30-day follow up.

IPD sharing plan summary

Stored in non-publicly available repository